Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A
Third Department of Internal Medicine, Hamamatsu University School of Medicine, Japan.
Chest. 1995 Feb;107(2):330-4. doi: 10.1378/chest.107.2.330.
To examine the diagnostic and prognostic value of myocardial scintigraphy using thallium-201 and gallium-67 in cardiac sarcoidosis.
Twenty-five patients with sarcoidosis.
All patients underwent myocardial thallium-201 scintigraphy. Six patients with myocardial thallium-201 defects were classified into group A and another 19 without defects were classified into group B. Between group A and B, we compared the results of other noninvasive examinations, including standard 12-lead ECG, 24 h ambulatory ECG, chest radiography, measurements of serum angiotensin-converting enzyme (ACE) and lysozyme levels, and gallium-67 scintigraphy.
Proportions of subjects who had varying degrees of heart block, severe ventricular arrhythmias (more than or equal to third grade of Lown's classification), and high levels of serum ACE and lysozyme levels were not different between these two groups (p > 0.05). Although an enlarged cardiothoracic ratio was more frequent in group A (p < 0.05), bilateral hilar lymphadenopathy was more frequent in group B (p < 0.01). Four patients of group A and 15 of group B underwent gallium-67 scintigraphy. Although no subjects of group B had myocardial uptake of gallium-67, two of four group A patients showed cardiac uptake. These four group A patients were treated with corticosteroids. The therapy provided clinical and scintigraphic improvement in two patients with myocardial gallium-67 uptake, although it did no improvement in the other two patients without gallium-67 uptake.
When cardiac sarcoidosis was diagnosed according to myocardial thallium-201 defects, other noninvasive examinations were not useful to detect this disease. However, gallium-67 uptake may predict the efficacy of corticosteroids. Thus, the combination of thallium-201 and gallium-67 scintigraphy may be useful not only in diagnosis of cardiac sarcoidosis but also in prediction of effects of corticosteroids.
探讨使用铊-201和镓-67心肌闪烁显像在心脏结节病中的诊断和预后价值。
25例结节病患者。
所有患者均接受铊-201心肌闪烁显像。6例铊-201心肌显像有缺损的患者被分为A组,另外19例无缺损的患者被分为B组。在A组和B组之间,我们比较了其他无创检查的结果,包括标准12导联心电图、24小时动态心电图、胸部X线摄影、血清血管紧张素转换酶(ACE)和溶菌酶水平的测定以及镓-67闪烁显像。
两组间出现不同程度心脏传导阻滞、严重室性心律失常(大于或等于Lown分级三级)以及血清ACE和溶菌酶水平升高的受试者比例无差异(p>0.05)。虽然A组心胸比率增大更为常见(p<0.05),但B组双侧肺门淋巴结肿大更为常见(p<0.01)。A组4例患者和B组15例患者接受了镓-67闪烁显像。虽然B组没有受试者出现心肌摄取镓-67,但A组4例患者中有2例出现心脏摄取。这4例A组患者接受了皮质类固醇治疗。该治疗使2例有心肌镓-摄取的患者在临床和闪烁显像方面得到改善,而另外2例无镓-67摄取的患者则无改善。
根据铊-201心肌缺损诊断心脏结节病时,其他无创检查对检测该病无用。然而,镓-67摄取可能预测皮质类固醇的疗效。因此,铊-201和镓-67闪烁显像联合使用不仅可能有助于心脏结节病的诊断,还可能有助于预测皮质类固醇的疗效。